Patents by Inventor Dessislava Vaneva MARINOVA

Dessislava Vaneva MARINOVA has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240382575
    Abstract: The present invention refers to a freeze-dried composition consisting of an isolated microorganism belonging to the Mycobacterium tuberucolosis complex, preferably a M. tuberculos clinical isolate, more preferably M. tuberculosis clinical isolate, characterized in that it comprises a PhoP? phenotype by the inactivation by a genetic deletion of the Rv0757 gene and the deletion of a second gene, Rv2930 (fadD26), that prevents PDIM production (PDIM? phenotype) (the MTBVAC strain), and sucrose and sodium glutamate as stabilizers or excipients. The present invention further refers to the reconstituted composition obtained by adding water, preferably sterilized water for injection, to the freeze-dried composition as well as uses thereof, in particular for use as a prophylactic agent to those at risk of infection with M. tuberulosis or those at risk of developing tuberculosis disease, or as secondary agents for treating infected tuberculosis patients.
    Type: Application
    Filed: July 30, 2024
    Publication date: November 21, 2024
    Inventors: Carlos MARTÍN MONTAÑES, Juan Ignacio AGUILÓ ANENTO, Jesús Ángel GONZALO ASENSIO, Dessislava Vaneva MARINOVA, Santiago UGANDA MAÍZ, Esteban RODRÍGUEZ SÁNCHEZ, Eugenia PUENTES COLORADO, Concepción FERNÁNDEZ ÁLVAREZ-SANTULLANO
  • Patent number: 11826411
    Abstract: The present invention refers to a freeze-dried composition consisting of an isolated microorganism belonging to the Mycobacterium tuberculosis complex, preferably a M. tuberculosis clinical isolate, more preferably M. tuberculosis clinical isolate, characterized in that it comprises a PhoP? phenotype by the inactivation by a genetic deletion of the Rv0757 gene and the deletion of a second gene, Rv2930 (fadD26), that prevents PDIM production (PDIM? phenotype) (the MTBVAC strain), and sucrose and sodium glutamate as stabilizers or excipients. The present invention further refers to the reconstituted composition obtained by adding water, preferably sterilized water for injection, to the freeze-dried composition as well as uses thereof, in particular for use as a prophylactic agent to those at risk of infection with M. tuberculosis or those at risk of developing tuberculosis disease, or as secondary agents for treating infected tuberculosis patients.
    Type: Grant
    Filed: February 19, 2019
    Date of Patent: November 28, 2023
    Assignees: UNIVERSIDAD DE ZARAGOZA, BIOFABRI S.L.
    Inventors: Carlos Martín Montañes, Juan Ignacio Aguiló Anento, Jesús Ángel Gonzalo Asensio, Dessislava Vaneva Marinova, Santiago Uganda Maíz, Esteban Rodríguez Sánchez, Eugenia Puentes Colorado, Concepción Fernández Álvarez-Santullano
  • Publication number: 20230330201
    Abstract: The present invention refers to a freeze-dried composition consisting of an isolated microorganism belonging to the Mycobacterium tuberucolosis complex, preferably a M. tuberculos clinical isolate, more preferably M. tuberculosis clinical isolate, characterized in that it comprises a PhoP? phenotype by the inactivation by a genetic deletion of the Rv0757 gene and the deletion of a second gene, Rv2930 (fadD26), that prevents PDIM production (PDIM? phenotype) (the MTBVAC strain), and sucrose and sodium glutamate as stabilizers or excipients. The present invention further refers to the reconstituted composition obtained by adding water, preferably sterilized water for injection, to the freeze-dried composition as well as uses thereof, in particular for use as a prophylactic agent to those at risk of infection with M. tuberulosis or those at risk of developing tuberculosis disease, or as secondary agents for treating infected tuberculosis patients.
    Type: Application
    Filed: April 28, 2023
    Publication date: October 19, 2023
    Inventors: Carlos MARTÍN MONTAÑES, Juan Ignacio AGUILÓ ANENTO, Jesús Ángel GONZALO ASENSIO, Dessislava Vaneva MARINOVA, Santiago UGANDA MAÍZ, Esteban RODRÍGUEZ SÁNCHEZ, Eugenia PUENTES COLORADO, Concepción FERNÁNDEZ ÁLVAREZ-SANTULLANO
  • Publication number: 20230263837
    Abstract: The present invention is directed to a live-attenuated Mycobacterium tuberculosis composition comprising an isolated microorganism belonging to a M. tuberculosis MTB VAC strain having a i) PhoP? phenotype by the inactivation by a genetic deletion of the Rv0757 gene, wherein the open-reading frame (ORF) sequence of phoP consists of SEQ ID NO 4, and ii) the deletion of a second gene, Rv2930 (fadD26), that prevents PDIM production (PDIM? phenotype), wherein the open-reading frame (ORF) sequence of fadD26 consists of SEQ ID NO 2, for use in therapy in a human subject in need thereof, wherein the composition is administered to said subject via pulmonary delivery.
    Type: Application
    Filed: September 28, 2020
    Publication date: August 24, 2023
    Inventors: Juan Ignacio AGUILÓ, Carlos MARTÍN MONTAÑES, Raquel TARANCÓN ÍÑIGUEZ, Elena MATA LOZANO, Santiago URANGA MAÍZ, Dessislava VANEVA MARINOVA
  • Publication number: 20230165948
    Abstract: The present invention refers to a freeze-dried composition consisting of an isolated microorganism belonging to the Mycobacterium tuberculosis complex, preferably a M. tuberculosis clinical isolate, more preferably M. tuberculosis clinical isolate, characterized in that it comprises a PhoP? phenotype by the inactivation by a genetic deletion of the Rv0757 gene and the deletion of a second gene, Rv2930 (fadD26), that prevents PDIM production (PDIM? phenotype) (the MTB VAC strain), and sucrose and sodium glutamate as stabilizers or excipients. The present invention further refers to the reconstituted composition obtained by adding water, preferably sterilized water for injection, to the freeze-dried composition as well as uses thereof, in particular for use as a prophylactic agent to those at risk of infection with M. tuberculosis or those at risk of developing tuberculosis disease, or as secondary agents for treating infected tuberculosis patients.
    Type: Application
    Filed: February 19, 2019
    Publication date: June 1, 2023
    Inventors: Carlos MARTÍN MONTAÑES, Juan Ignacio AGUILÓ ANENTO, Jesús Ángel GONZALO ASENSIO, Dessislava Vaneva MARINOVA, Santiago UGANDA MAÍZ, Esteban RODRÍGUEZ SÁNCHEZ, Eugenia PUENTES COLORADO, Concepción FERNÁNDEZ ÁLVAREZ-SANTULLANO